1H25 earnings saved by sub-brands; Maintain BUY

PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE MORE REPORTS FROM BLOOMBERG: RESP CMBR <GO> OR http://www.cmbi.com.hk 1 MN 1 Sep 2025 CMB International Global Markets | Equity Research | Company Update Proya Cosmetics (603605 CH) Proya Cosmetics (603605 CH) - 1H25 earnings saved by sub-brands; Maintain BUY 1H25 earnings saved by sub-brands; Maintain BUY Proya delivered 1H25 revenue and attributable NP growth of +7.2% and +13.8% YoY respectively, missing BBG consensus by 3%/4% primarily driven by sustained momentum across sub-brands and continued pressure on core brand Proya. GP margin improvement was partly offset by heavier selling expenses on 618 promotion and sub-brands marketing. The company announced HK listing plan to accelerate overseas expansion. We trim our TP by 3% to RMB129.83 to reflect lower earnings forecast, based on 30x 2025E P/E, Maintain BUY.  Sub-brands growth cushioned pressure of core brand. Rev. of core brand Proya dropped 0.1% YoY in 1H25 on a high base and fiercer competition. Sub-brands TIMAGE/OR/ INSBAHA sustained high growth with revenue up 21/102/80% YoY, with their combined revenue contribution lifted to 20.2% in 1H25, up 4.7ppts YoY. Looking forward, management has laid out a clear plan to enrich the product matrices across sub-brands: TIMAGE will iterate base-makeup technologies; OR will focus on anti-hair-loss solutions with aromatherapy concepts; and INSBAHA will deepen niche color cosmetics. International expansion is set to accelerate, with OR launches planned in Hong Kong and Japan and Hapsode rollout in Southeast Asia. The proposed HK listing should also provide capital and branding support to scale overseas and consolidate the company’s multi-brand advantages.  7M25 sales largely in line with the industry. In 1H25, offline sales dropped 21.3% YoY while online sales grew steadily at 9.2% YoY (self-operated +4.2% / distribution +25.9%). Based on our tracked cosmetics database, Proya’s GMV (covered Proya/Timage/OR) on Taobao & Douyin combined grew 4% YoY in 7M25, slightly slower than industry’s 5%.  Cost savings outcome partly offset by rising marketing expenses. Gross margin expanded by 3.6ppt YoY to 73.4% in 1H25 thanks to cost control efforts such us shifting freebies from “mini” to “mid-size” to reduce packaging & unit marketing costs. SG&A ratio rose by 2.6ppt YoY given heavier 618 promotions cost and celebrity endorsements for sub-brands. With 2H marketing will likely remain elevated around 11.11 shopping festival, we expect the full-year selling expense ratio to trend higher.  Maintain BUY. We maintain our BUY rating, with TP cut 3% to RMB 129.83, on 30x 2025E P/E. Risks: worse-than-expected consumption sentiment, intensifying competition, and raw material price hike etc. Target Price RMB129.83 (Previous TP RMB133.86) Up/Downside 54.9% Current Price RMB83.83 China Consumer Staples Miao ZHANG (852) 3761 8910 zhangmiao@cmbi.com.hk Stock Data Mkt Ca

立即下载
医药生物
2025-09-02
招银国际
Miao Zhang
6页
0.93M
收藏
分享

[招银国际]:1H25 earnings saved by sub-brands; Maintain BUY,点击即可下载。报告格式为PDF,大小0.93M,页数6页,欢迎下载。

本报告共6页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共6页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
中泰医药主要覆盖公司及估值一览
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
本期中泰医药小组研究报告汇总
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
中国成都中药材价格指数图
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
8 月涨幅前 15 位公司(扣除 ST 股)图表 21:8 月跌幅前 15 位公司(扣除 ST 股)
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
医药子板块估值对比(平均市盈率统计为 2010 年至今)
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
医药板块整体估值溢价(扣除金融板块,2010 年至今)
医药生物
2025-09-01
来源:医药生物行业9月月报:Q2环比改善、复苏有望延续,持续看好创新主线
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起